Skip to main content
. 2021 Apr 29;28(25):32095–32110. doi: 10.1007/s11356-021-14103-1

Table 3.

Emerging contaminants proposed as markers of untreated wastewater

Emerging contaminant Family/use Reasoning Evidence in the environment Ref. Literature wastewater data
Untreated wastewater concentration (ng L−1) Treatment removal (%) Untreated wastewater EF Treated wastewater EF Ref.
Caffeine Stimulant

High removal during wastewater treatment and low concentration variation

High removal during wastewater treatment

High removal during wastewater treatment

High removal during wastewater treatment

Elevated concentrations following CSO events A 1045–150,414 > 95 NA NA H
3400–6600 > 99 NA NA I
B 7000–73,000 81 to > 99 NA NA J
Caffeine loads in stream correlated with rainfall C 42,400–43,800 > 99 NA NA K
5250–9310 > 99 NA NA L
D 42,000 64 NA NA E

Elevated concentration at site of untreated wastewater discharge

Elevated concentrations following CSO events

5094–1,214,375 > 99 NA NA M
74,813 92 NA NA N
135,883–184,819 - NA NA O
Theophylline Bronchodilator High removal during wastewater treatment Elevated concentrations following CSO events D 1745–107,915 > 93 NA NA H
146,500 95 NA NA N
16,765–237,345 99 NA NA M
75,413–137,196 - NA NA O
Nicotine Stimulant High removal during wastewater treatment No decrease in environmental concentration following CSO event. E 17,000 87 NA NA E
87–9086 > 95 NA NA H
50–89,600 65 to 99 NA NA P
4874–11,866 99 NA NA M
7750 98 NA NA N
3340–8562 - NA NA O
Cotinine Stimulant metabolite High removal during wastewater treatment Elevated concentration at site of untreated wastewater discharge C 1972 82 NA NA N
1882–2437 - NA NA O
44–66 > 69 NA NA H
780–2880 91 to 99 NA NA J
3333–4892 > 99 NA NA M
Paracetamol Analgesic

High removal during wastewater treatment

High removal during wastewater treatment

High removal during wastewater treatment

No decrease in concentration following CSO event.

Elevated concentration at site of untreated wastewater discharge

Elevated concentrations following CSO events

E 61,000 99 NA NA E
68,107–482,687 ≥ 92 NA NA Q
C 7100–11,400 > 99 NA NA R
- > 90 NA NA S
D 136,887–343,620 > 99 NA NA M
138,164 99 NA NA N
Ibuprofen NSAID EF change during wastewater treatment. Surface water EFs were in the range of sewage overflows. F - - 0.73 0.50 F
9055–15,780 95 - - M
968–6328 > 85 - - Q
990–3300 > 95 0.85–0.89 0.47–0.67 T
1213–2058 - 0.79–0.86 0.63–0.68 U
- 17 to 99 0.73–0.90 0.60–0.76 V
12,907 90 - - N
Naproxen NSAID EF change during wastewater treatment due to chiral inversion. Surface water EFs were in the range of sewage overflows. F - - > 0.96 0.65–0.92 F
2925–5455 47 - - M
400–3504 > 57 - - Q
30–430 - > 0.99 0.88–0.91 W
1067–3202 - 0.98–0.99 0.93–0.96 U
- 24 to 89 0.88–0.90 0.71–0.86 V
13,660 74 - - N
Cocaine Stimulant High removal during wastewater treatment and low concentration variation Elevated environmental concentrations following CSO events. A 882–1575 > 99 NA NA A
21–1837 25 to ≥ 99 NA NA Q
5–209 37 to 91 NA NA H
92–753 93 to > 99 NA NA X
195–961 96 NA NA Y
430 83 NA NA N
397–694 - NA NA O
Benzoylecgonine Stimulant metabolite High removal during wastewater treatment and low concentration variation Elevated environmental concentrations following CSO events. A 1973–2544 > 98 NA NA A
126–3715 No removal to ≥ 99 NA NA Q
16–567 27 to 81 NA NA H
322–2258 93 to 99 NA NA X
545–3790 88 NA NA Y
1247 69 NA NA N
754–1604 - NA NA O
Amphetamine Stimulant High removal and change in EF during wastewater treatment. Elevated concentration at site of untreated wastewater discharge with EF value (0.43) typical of untreated UK wastewater C 255–12,020 ≥ 95 - - Q
64–368 > 99 0.32–0.46 - Z
3–3113 ≥ 89 0.16–0.44 0.00–0.29 AA
291–412 - 0.41–0.43 - O
17–3113 ≥ 89 - - H
288 77 - - N
Propranolol Beta-blocker Change in EF during wastewater treatment EF values in surface waters with untreated wastewater discharges were similar to EF values in untreated wastewater. G 13–250 - 0.49–0.54 0.30–0.44 G
54–100 28 - - A
110–1962 No removal to 35 - - Q
108–1130 59 to 78 - - R
122 5 - - N
28–56 No removal to 34 0.37–0.46 0.39–0.45 AB

A, Munro et al. 2019; B, Buerge et al. 2003; C, Ramage et al. 2019; D, Poopipattana et al. 2021; E, Benotti and Brownawell 2007; F, Khan et al. 2014; G, Fono and Sedlak 2005; H, Baker and Kasprzyk-Hordern 2013; I, Sui et al. 2010; J, Buerge et al. 2006; K, Thomas and Foster 2005; L, Froehner et al. 2011; M, Archer et al. 2017; N, Petrie et al. 2016; O, Castrignanò et al. 2016; P, Ekpeghere et al. 2018; Q, Kasprzyk-Hordern et al. 2009; R, Radjenović et al. 2009; S, Matsuo et al. 2011; T, Buser et al. 1999; U, Caballo et al., 2015; V, Matamoros et al. 2009; W, Suzuki et al. 2014; X, van Nuijs et al. 2009; Y, Postigo et al. 2010; Z, Kasprzyk-Hordern et al. 2010; AA, Kasprzyk-Hordern and Baker 2012; AB, López-Serna et al. 2013

Key: NSAID, nonsteroidal anti-inflammatory; EF, enantiomeric fraction; NA, not applicable; -, not measured; CSO, combined sewer overflow; SO, sewage overflow